Sigvotatug vedotin

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameSigvotatug vedotin
Drug Alias NameSGN-B6APF-08046047
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsMitosis inhibitorsApoptosis stimulants +[5] 
TargetsIntegrin beta-6Tubulin
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[34] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer (Beijing) Research and Development Co LtdIqvia Rds (Shanghai) Co LtdSeagen Inc +[5] 
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[14] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A